HIMS

T11.5% portfolio

Hims & Hers Health, Inc.

Next est. report 2026-11-09 · AMC

Archetypes '25: Trad Wives Archetypes '26: OptimizersBeauty '26: HaircareGLP-1 Long '24: GLP1 Equip/Distrib GLP-1 Long '24: Peptide Producers/Designers HaveNots Shorts '25: Premium Subscriptions Looksmaxxing '26: Skin Care & Body Treatment MedTech Long '26: Consumerized HealthcareRetail Shopping '25: Single-Vertical EcomSmall Themes '24: Value-Based Care

Loading…

Loading chart…

Overview

Hims & Hers Health, Inc. operates a digital health platform connecting nearly 3 million global subscribers with medical professionals for virtual care. It offer

Hims & Hers Health, Inc. operates a digital health platform connecting nearly 3 million global subscribers with medical professionals for virtual care. It offers personalized health and wellness solutions, including prescriptions for sexual health, skincare, hair care, weight loss, and hormone therapies. U.S. operations comprise ~82.6% of revenue, with international expansion and AI-native experiences driving growth, including new offerings like peptides and injectable testosterone.

Key Inputs And Sourcing

1. Branded GLP-1 Medications

component · Global · High

Source Explicitly mentioned as driving gross margin headwinds and working capital demands.

Confidence: high

2. Active Pharmaceutical Ingredients (APIs)

commodity · U.S., Global · unknown

Source Hims & Hers is investing in U.S.-based API manufacturing for peptides in its Menlo Park facility.

Confidence: high

3. Pharmacy Operations Labor

labor · U.S., International · unknown

Source Efficiencies are realized across pharmacy fulfillment operations as the subscriber base grows. The company has over 1 million square feet of pharmacy facilities.

Confidence: high

4. Licensed Medical Professionals

labor · Global · unknown

Source Costs associated with the provider network for virtual consultations and ongoing care.

Confidence: high

5. Lab Testing Services/Components

other · Global · unknown

Source Involves at-home blood collection and utilization of lab testing facilities.

Confidence: medium

6. Packaging Materials

packaging · Unknown · unknown

Source Implied by direct-to-consumer product fulfillment.

Confidence: medium

7. Shipping and Logistics Services

logistics · Global · unknown

Source Essential for direct-to-consumer delivery of products.

Confidence: medium

8. External AI Customer Support Vendors

other · Global · unknown

Source Hims & Hers is reducing reliance on these vendors as internal AI capabilities scale.

Confidence: medium

Industry Publications

[]

Economic Data Watch

1. Federal Reserve Economic Data (FRED) — Retail and Food Services Sales

Metric/field RSFS

Cadence monthly

Why it matters As a direct-to-consumer platform, Hims & Hers' revenue is directly impacted by overall consumer spending and retail activity. A strong retail sales environment suggests consumers have the disposable income and willingness to spend on health and wellness subscriptions.

Signal to watch Sustained or accelerating month-over-month growth indicates a favorable consumer spending environment.

Confidence: high

2. Federal Reserve Economic Data (FRED) — Personal Income and Outlays

Metric/field Disposable Personal Income (DPI)

Cadence monthly

Why it matters Disposable Personal Income reflects the income available to individuals after taxes, directly influencing their capacity to afford Hims & Hers' subscription-based health and wellness services.

Signal to watch Consistent growth in DPI suggests consumers have more financial flexibility for discretionary health spending.

Confidence: high

3. Bureau of Labor Statistics (BLS) — Consumer Price Index (CPI)

Metric/field CPI for All Urban Consumers: Medical Care Services in U.S. City Average (CUUR0000SAM2)

Cadence monthly

Why it matters Hims & Hers positions itself as an affordable alternative to traditional healthcare. Tracking the CPI for medical care services highlights the cost pressures in the broader healthcare system, potentially increasing the appeal of Hims & Hers' value proposition.

Signal to watch Rising medical care service costs could increase demand for more affordable digital health solutions.

Confidence: high

4. Federal Reserve Economic Data (FRED) — Labor Force Statistics

Metric/field Civilian Unemployment Rate (UNRATE)

Cadence monthly

Why it matters The unemployment rate is a key indicator of economic health and consumer confidence. Higher unemployment can lead to reduced discretionary spending on non-essential health and wellness services, impacting subscriber growth and retention.

Signal to watch A stable or declining unemployment rate suggests a stronger economic environment and greater consumer capacity for subscriptions.

Confidence: high

5. World Health Organization (WHO), Centers for Disease Control and Prevention (CDC) — Global Health Observatory (GHO) data / National Center for Health Statistics (NCHS)

Metric/field Global Obesity Prevalence Rate (Adults)

Cadence annually

Why it matters Hims & Hers has significantly expanded its weight loss offerings, including GLP-1s, which is a major growth driver. The global obesity prevalence rate indicates the total addressable market and long-term demand for these services.

Signal to watch Sustained or increasing obesity rates signal a growing long-term market opportunity for weight loss solutions.

Confidence: high

Free Alt Data Watch

1. Google Trends — Search Interest

Metric/field Relative Search Volume for 'Hims' and 'Hers'

Cadence daily

Why it matters Directly measures consumer awareness and interest in the company's core brands, indicating brand strength and potential for organic subscriber acquisition.

Signal to watch Increasing or sustained high search interest suggests strong brand visibility and consumer engagement.

Confidence: high

2. Google Trends — Search Interest

Metric/field Relative Search Volume for 'weight loss medication' and 'GLP-1'

Cadence daily

Why it matters Hims & Hers' weight loss offerings, particularly GLP-1s, are a significant growth area. Tracking broader search interest in these categories indicates market demand and potential for Hims & Hers to capture new subscribers.

Signal to watch Rising search interest in weight loss medications and GLP-1s points to an expanding market and potential for Hims & Hers' related services.

Confidence: high

3. Apple App Store / Google Play Store — App Rankings and Reviews

Metric/field Hims & Hers Health app 'Overall Ranking' and 'Average User Rating'

Cadence daily

Why it matters As a digital health platform, app performance is crucial. High rankings and positive reviews indicate strong user acquisition, engagement, and satisfaction with the AI-native experience.

Signal to watch Improving app rankings and consistently high user ratings suggest effective user acquisition and a positive customer experience.

Confidence: medium

4. Reddit Community Analysis — Subreddit Activity

Metric/field Mentions and Sentiment for 'Hims' and 'Hers' in r/telehealth, r/weightloss, r/menshealth, r/womenshealth

Cadence weekly

Why it matters Reddit communities often reflect genuine consumer discussions, concerns, and experiences. Monitoring mentions and sentiment can provide early signals on brand perception, product effectiveness, and emerging trends.

Signal to watch An increase in positive mentions and constructive discussions, particularly regarding new offerings or the AI experience, indicates growing user satisfaction and community acceptance.

Confidence: medium

5. Federal Trade Commission (FTC) Public Filings — Legal Filings and Press Releases

Metric/field Status and updates on FTC complaint against Hims & Hers

Cadence event_driven

Why it matters The FTC complaint introduces regulatory and legal risk, which can impact investor sentiment and potentially operations. Monitoring its status provides crucial information on potential outcomes and financial impacts.

Signal to watch Resolution or favorable developments in the FTC complaint would reduce regulatory uncertainty.

Confidence: high

Paid Alt Data Watch

1. Sensor Tower / Apptopia — Mobile App Intelligence

Metric/field Hims & Hers Health app 'Monthly Active Users (MAU)' and 'Total Downloads'

Cadence monthly

Why it matters Provides granular insights into the scale of user engagement and acquisition for Hims & Hers' primary digital interface, directly correlating with subscriber growth and platform stickiness.

Signal to watch Consistent growth in MAU and downloads indicates strong user adoption and sustained platform engagement.

Confidence: high

2. SimilarWeb / Semrush — Website Traffic & Engagement

Metric/field Total Website Visits (hims.com, forhers.com) and 'Traffic Sources (Direct, Organic Search, Paid Search)'

Cadence monthly

Why it matters Website traffic is a key indicator of top-of-funnel interest and marketing effectiveness. Analyzing traffic sources helps understand the efficiency of marketing spend and organic reach.

Signal to watch Increasing total website visits, especially from organic search, suggests effective brand building and efficient customer acquisition.

Confidence: high

3. Revelio Labs / LinkUp — Labor Market Analytics

Metric/field Hims & Hers Health, Inc. 'Job Postings (AI/Technology roles)' and 'Employee Headcount (overall and by department)'

Cadence weekly

Why it matters Hims & Hers is heavily investing in AI and technology talent. Tracking job postings, particularly for AI roles, indicates the pace and scale of their strategic investments and future innovation capabilities.

Signal to watch An increase in AI/technology job postings and overall headcount growth signals accelerated investment in strategic growth areas.

Confidence: high

4. Earnest Research / Second Measure — Consumer Transaction Data

Metric/field Hims & Hers subscriptions 'Subscriber Growth (YoY)' and 'Churn Rate'

Cadence monthly

Why it matters Provides direct, real-time insights into the core business metrics of subscriber acquisition and retention, which are critical for a subscription-based model. This data can validate or contradict company-reported figures.

Signal to watch Strong year-over-year subscriber growth and declining churn rates indicate a healthy and sticky customer base.

Confidence: high

5. Brandwatch / NetBase Quid — Social Media Listening & Analytics

Metric/field Hims & Hers brand 'Social Media Sentiment (Net Sentiment Score)' and 'Share of Voice (vs. key competitors)'

Cadence daily

Why it matters Monitors public perception and competitive standing across social media, which is highly relevant for a consumer-facing brand. Sentiment can influence brand trust and subscriber acquisition.

Signal to watch Improving net sentiment and an increasing share of voice against competitors suggest positive brand perception and market penetration.

Confidence: medium

Search Keywords Brand Product

Hims
Hers
Wegovy
Zepbound
Sermorelin
Glutathione
NAD+
testosterone therapy
peptide therapy
AI-native health platform
telehealth
digital health
weight loss drugs
hormone therapy
longevity medicine
online pharmacy
direct-to-consumer healthcare
AI in healthcare

Search Keywords Event Phrases

Eucalyptus acquisition
Hims & Hers Q2 earnings
PCAC peptide recommendations

Search Keywords Policy Regulatory

FDA peptide regulation
FTC lawsuit Hims
503A peptide list

What They Do (Plain English & Analogies): Hims & Hers Health, Inc. acts like a digital health hub, similar to a 'Netflix for healthcare,' connecting people directly with licensed medical professionals online for virtual consultations and ongoing care. They deliver a wide range of health and wellness products straight to consumers' homes, including prescription medications, over-the-counter drugs, devices, cosmetics, and supplements. Their main focus areas are general wellness, sexual health, skincare, hair care, weight loss, and hormone therapies. The company is building an 'AI-native' health experience, integrating AI coaches, support agents, care teams, clinicians, and pharmacies into one unified system. This aims to provide personalized, proactive, and widely accessible care, essentially making expensive 'concierge care' affordable for everyone globally.
Very Brief History: Founded in 2017, Hims initially focused on men's health products before expanding to include a women's brand, Hers, and diversifying into dermatology, sexual health, and weight management. After going public via SPAC in 2021, the company shifted towards vertical integration, building its own compounding pharmacies and lab operations. Recent acquisitions include YourBio for at-home blood sampling technology in Q1 2026 and Eucalyptus in June 2026 to expand its international footprint. The company has also accelerated its focus on GLP-1s for weight loss, whole-body labs, and hormone therapies.
"Street Stereotype": On the Street, HIMS is often seen as a digital subscription health play that initially appeared to be a marketing-led 'Instagram of pharmacies.' However, it is now recasting itself as a vertically integrated telehealth platform. Investors are divided, with some viewing it as a high-growth, platform-driven healthcare disruptor, while others perceive it as a GLP-1/compounding-dependent story facing regulatory and margin risks. The recent emphasis on AI and global expansion, alongside ongoing FTC litigation, adds new dimensions to this perception.
Subsidiaries On Linked In*: Hims & Hers — Parent company and consumer brands; LinkedIn: hims-hers-health
Zava — Europe telehealth, acquired; LinkedIn: zava-health
Livewell — Canada telehealth, acquired; LinkedIn: livewell-health
YourBio Health — At-home microneedle blood sampling technology, acquired/closed Q1 2026; LinkedIn: yourbio-health
Eucalyptus — Acquired and closed in June 2026, expands U.K./Australia/Japan footprint; LinkedIn: eucalyptus-health
Apostrophe — Dermatology acquisition; LinkedIn: apostrophe-skin
Customer Sectors & Example Clients: Hims & Hers primarily serves individual consumers (direct-to-consumer subscribers) across various health and wellness needs, including general wellness, sexual health, dermatology, weight loss, hormone therapy, and preventive diagnostics. Secondary customers and partners include retail and wholesale partners for product distribution. A specific publicly referenced partner is Novo Nordisk, for GLP-1 products like Wegovy.
New Customers / Segments They'Re Targeting: Hims & Hers is targeting customers seeking proactive, personal, and widely accessible healthcare, aiming to make 'concierge care' affordable globally. They are expanding into new, more complex categories such as injectable and oral testosterone replacement therapy, menopause therapy for women, and peptide therapies (including sermorelin, glutathione, and NAD+ by year-end, and others pending FDA approval). They are also focusing on metabolic health with a broader assortment of GLP-1s, and longevity medicine. The company's AI-native health experience is designed to attract and retain customers across all specialties by providing a unified, personalized, and highly engaging care journey.
Sales Geographies And Expansion Plans: Hims & Hers currently sells its products primarily in the U.S. across all 50 states and Washington, D.C. The company has a growing international footprint, with existing operations in Europe (through ZAVA) and in Canada (through Livewell). Following the acquisition of Eucalyptus in June 2026, they have deepened their presence in Europe and extended their reach to Australian and Japanese consumers. The company now has three international markets (U.K., Australia, Germany) pacing above a $100 million annual run rate, with Canada also on track to join this group. They plan to make their comprehensive experience available to customers in all specialties across their global markets, with aggressive investment in these international markets to build category leadership.
How Key Themes May Help/Hurt: The buildout of the 'GLP-1 Long '24: Peptide Producers/Designers' theme is a significant tailwind for Hims & Hers. The company is actively developing a best-in-class peptides experience, including U.S.-manufactured products, clinical guidance, and ongoing blood testing. The recent positive recommendations from the PCAC meeting for six of seven peptides signal a significant expansion of the compounded therapy market, which Hims & Hers is well-positioned to capitalize on with its verticalized infrastructure and U.S.-based API manufacturing facility. This could unlock a substantial new revenue stream and expand their addressable market in longevity and preventative care. However, the theme also presents risks, particularly stringent regulatory approval processes and evolving guidance for novel peptide therapies and compounded peptides. Hims & Hers is currently awaiting 'full and final rule making' from the FDA before bringing the recommended peptides to market, which introduces uncertainty and potential delays. Additionally, significant investment costs in R&D, manufacturing, and clinical protocols for peptides could pressure near-term profitability, as seen with the company's overall investment strategy impacting gross margins and cash flow.

3 Main Long-Term Bull Details

AI-Native, Vertically Integrated, Global Platform: Hims & Hers is building a unique, AI-powered, closed-loop health experience that integrates care teams, clinicians, and pharmacies, supported by over 1 million square feet of verticalized infrastructure and a global footprint (including the recent Eucalyptus acquisition). This creates a defensible moat, enabling personalized care at scale, driving efficiencies, and fostering deeper customer relationships, with AI investments expected to pay back within 12-18 months.
Massive TAM Expansion & Rapid Specialty Rollouts: The company is aggressively expanding its total addressable market by entering and rapidly scaling new, large categories such as branded GLP-1s for weight loss, low testosterone, menopause, labs, and future peptide therapies. This repeatable go-to-market capability across underpenetrated categories, informed by patient data, positions them for sustained long-term growth and cross-sell opportunities, with testosterone scaling faster than any other specialty outside of weight loss.
Strong Financial Position & Strategic Investment Capacity: With over $840 million in cash and short-term investments, a $400 million receivables facility, and a $400 million convertible debt offering, Hims & Hers has the balance sheet strength to continue aggressive investments in AI, technology, new specialties, and international expansion. These investments are expected to drive long-term value, improve unit economics, and contribute to ambitious 2030 financial targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.

3 Main Long-Term Bear Details

Regulatory & Litigation Risks: The company faces ongoing regulatory scrutiny, including an FTC complaint filed on July 29, 2026, alleging deceptive billing, difficult cancellations, and improper sharing of sensitive health data. This, alongside uncertainty surrounding FDA guidance on peptide therapies (e.g., waiting on 'full and final rule making' for recommended peptides), could materially impact revenue, operations, and market perception.
Near-Term Margin Compression & Execution Risk: Hims & Hers is undergoing a period of heavy investment in AI, technology, new specialties (like branded weight loss and peptides), and international expansion, which is leading to near-term gross margin compression (64% in Q2 2026, down 6 points QoQ). If these investments do not yield expected scale, efficiencies, or profitability, or if international integrations face challenges, the path to long-term margin targets could be delayed.
Intensifying Competition & Consumer Trust Issues: The telehealth, weight loss, and emerging peptide markets are highly competitive, with branded pharma companies (e.g., LillyDirect) and other digital health providers. This intense competition, coupled with potential pricing pressure and the inherent volatility of new and evolving categories, could challenge Hims & Hers' market share and profitability. Furthermore, the FTC lawsuit raises concerns about consumer trust, which is critical for a direct-to-consumer health platform.

Competitors And Differentiation: Hims & Hers believes its investment in AI and technology delivers a health experience no other company can replicate, building something entirely new and increasingly difficult to replicate. Its AI-native platform aims to deliver a unified health experience that no other peer or large language model (LLM) can match, supporting customers through their entire health journey unlike frontier AI companies. The company differentiates itself by making its platform completely AI-native, creating an integrated, personal experience, rather than just tacking on minor improvements to existing systems. Hims & Hers sees its advantage as being an everyday partner to customers, not just a chatbot, believing this is something only they can do well. The company asserts its growing scale and increasing investment in technology and infrastructure make it structurally more efficient than anyone else in healthcare, allowing it to play offense with a strong balance sheet and cost structure others cannot sustain. They believe their capabilities and scale provide structural advantages for investing in key growth areas like weight loss and international markets in ways competitors cannot. Delivering more for less is how they extend their platform's advantages, a feat few in consumer health can match. The company's global scale is becoming a competitive advantage, expanding its total addressable market and value to industry partners, strengthening network effects. Its closed-loop proprietary data flywheel, encompassing consumer intake, diagnosis, treatment, provider decisions, and outcomes in a single stack, is difficult for competitors to recreate. The verticalized infrastructure and U.S.-based peptide manufacturing facility provide advantages in quality, purity, reliability, and brand trust that will be difficult for others to match.
Recent Performance & What The Market'S Focused On: Hims & Hers reported strong Q2 2026 revenue growth of nearly 40% year-over-year to over $753 million, driven by international expansion (up over 17-fold year-over-year to $131 million) and accelerated domestic growth (up 16% year-over-year). The company added over 300,000 net new subscribers, bringing its global subscriber base to nearly 3 million. Adjusted EBITDA in Q2 was $60 million, representing an 8% margin. However, gross margins compressed to 64% (down 6 points quarter-over-quarter) due to the mix shift towards branded weight loss products and international revenue. Operating cash flow was negative $36 million and free cash flow was negative $68 million, primarily due to working capital demands from branded weight loss offerings and non-recurring costs related to the Eucalyptus acquisition, restructuring, and FTC litigation. The company raised its full-year 2026 revenue outlook to $3.1 billion to $3.3 billion and expects adjusted EBITDA between $275 million and $325 million. The market is focused on the company's ability to sustain revenue acceleration, achieve a 'meaningful step-up' in adjusted EBITDA in the second half of 2026, the successful integration and profitability of international operations, the progress and regulatory clarity for peptide offerings, and the outcome of the FTC litigation.

Revenue Segments And Estimated Mix: {"segments":[{"segment_name":"U.S. Operations","estimated_mix":"~82.6% (Q2 2026)","source_or_comment":"Q2 2026 earnings transcript","yoy_or_trend_comment":"Accelerated to 16% year-over-year in Q2 2026, driven by expanded weight loss assortment and new specialties like low testosterone."產業: 1},{"segment_name":"International Operations","estimated_mix":"~17.4% (Q2 2026)","source_or_comment":"Q2 2026 earnings transcript","yoy_or_trend_comment":"Increased over 17-fold year-over-year to $131 million in Q2 2026, with Eucalyptus contributing ~$40 million; expected to operate at or near breakeven as scale is prioritized."}]}
Product Brands: Hims
Hers
Wegovy
Zepbound
Sermorelin
Glutathione
NAD+
Juniper
Zava
Livewell
Apostrophe
YourBio
Pilot
Kin

Bull / Bear Details

Hims & Hers is rapidly transforming into a global, AI-native health ecosystem, driving accelerated growth through robust international expansion, successful bra

Thesis

Hims & Hers is rapidly transforming into a global, AI-native health ecosystem, driving accelerated growth through robust international expansion, successful branded GLP-1 offerings, and scaling new specialties like testosterone. Significant investments in AI are enhancing customer experience and efficiency, while verticalized infrastructure supports future peptide offerings. Despite near-term margin compression and legal challenges, the company's strong financial position and raised 2026 outlook reinforce confidence in its ambitious 2030 targets. (Updated: 2026-08-11)

Bull case

Hims & Hers is demonstrating exceptional global expansion, with Q2 international revenue surging over 17-fold year-over-year to $131 million. The successful acquisition of Eucalyptus has established three international markets (UK, Australia, Germany) each pacing above a $100 million annual run rate, significantly broadening its addressable market and creating a powerful multi-market revenue engine for durable growth.
The company's strategic investments in AI and technology are delivering a unique, AI-native health experience, driving significant customer engagement (3x messages for Hers weight loss) and operational efficiencies (50% reduction in non-clinical tasks). These advancements are expected to improve retention, lower costs, and accelerate the rollout of new categories, with AI investments projected to pay back within 12-18 months.
Hims & Hers continues to successfully scale new, higher-complexity specialties, with testosterone scaling faster than any other offering outside weight loss and expected to reach a $100 million annual run rate soon. Furthermore, the company is actively preparing for peptide offerings, leveraging its U.S.-based API manufacturing facility and clinical expertise to ensure a high-quality, compliant market entry for allowed peptides by year-end.

Bear case

Hims & Hers faces continued near-term margin compression and significant investment costs. Q2 2026 saw adjusted gross margins at 64%, down 6 points quarter-over-quarter, and operating cash flow was negative $36 million, with free cash flow negative $68 million, primarily due to working capital demands from branded weight loss offerings. Gross margins are expected to remain below historical levels as lower-margin weight loss and international segments scale.
The company is facing new legal and regulatory scrutiny, with the FTC filing a complaint on July 29 after a nearly three-year investigation. Hims & Hers incurred approximately $81 million in non-recurring costs in Q2, including legal contingency accruals, and intends to vigorously defend its position, introducing uncertainty and potential financial impact from ongoing litigation.
While international expansion is a key growth driver, it presents execution challenges and near-term profitability drag. The international business is expected to operate at or near breakeven on an adjusted EBITDA basis in 2026 as the company prioritizes scale, requiring aggressive investment and posing risks to achieving profitability in these new regions within projected timelines.

Bull / Bear Case

Bear Case: Hims & Hers faces continued near-term margin compression and significant investment costs, with Q2 adjusted gross margins at 64% (down 6 points quarter-over-quarter) and expectations for gross margins to remain below historical levels as lower-margin weight loss and international segments scale. The company reported negative operating cash flow of $36 million and negative free cash flow of $68 million in Q2, primarily due to working capital demands from branded weight loss offerings. A new legal and regulatory overhang exists with the FTC filing a complaint on July 29, 2026, resulting in $81 million in non-recurring costs in Q2 and introducing uncertainty and potential financial impact from ongoing litigation. While international expansion is a key growth driver, it is expected to operate at or near breakeven on an adjusted EBITDA basis in 2026, posing execution challenges and a near-term profitability drag.
Bull Case: Hims & Hers is rapidly expanding its global footprint, with Q2 international revenue surging over 17-fold and three international markets now exceeding a $100 million annual run rate, significantly broadening its addressable market. Strategic investments in AI and technology are creating a unique, AI-native health experience, driving 3x customer engagement in weight loss and a 50% reduction in non-clinical tasks, with AI investments expected to pay back within 12-18 months. The company is successfully scaling new, higher-complexity specialties like testosterone, which is growing faster than any other offering outside weight loss, and is actively preparing for peptide offerings with U.S.-based API manufacturing. With a strong balance sheet and raised 2026 revenue outlook of $3.1 billion to $3.3 billion, Hims & Hers is confident in achieving its ambitious 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.
More Compelling & Why: Bear. Despite strong revenue growth, the company's negative free cash flow of $68 million in Q2 and projected continued gross margin compression make the bear case more compelling, especially if the stock trades at a high Price/Sales multiple (e.g., above 5-6x 2026 estimated revenue). The strongest argument for the bear case is the combination of significant investment-driven margin compression, negative cash flow, and the unquantified risk of the FTC lawsuit. My view would flip to bullish with consistent positive free cash flow generation for two consecutive quarters, a clear and favorable resolution to the FTC lawsuit, and sustained adjusted gross margin expansion above 65% while maintaining robust revenue growth.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
AI Integration & Efficiency Gains	AI is central to Hims & Hers' strategy for personalized care, operational efficiency, and cost savings. Demonstrating tangible benefits validates their investment and competitive advantage, potentially leading to lower prices and expanded market reach.	Continued reduction in non-clinical tasks (Q2 saw nearly 50% reduction), sustained 3x message engagement in AI-native experiences, lower cancellation rates for AI-enabled cohorts, and progress on new AI talent hires and the Menlo Park AI R&D lab.	Bullish: Continued reduction in non-clinical tasks by >50%, sustained high customer engagement, and lower cancellation rates for AI-enabled cohorts.	Company earnings calls, investor presentations, and press releases.	Google Trends: 'Hims & Hers AI', 'telehealth AI', 'personalized health AI'. Reddit communities like r/Hims, r/Hers for user sentiment on new features.	Thinknum: AI/Engineering job postings growth for Hims & Hers. Apptopia/Sensor Tower: App engagement metrics (messages sent, time in app) for Hims & Hers.
Peptide Therapy Launch & Regulatory Progress	Peptides represent a significant new market opportunity for longevity and wellness. Clarity on FDA regulation and Hims & Hers' ability to launch safely and quickly will drive future revenue and market leadership.	Official FDA 'full and final rule making' for the 6-7 peptides recommended by PCAC. Launch of already allowed peptides (sermorelin, glutathione, NAD+) by end of 2026. Updates on U.S.-based API manufacturing (e.g., BPC-157 stability testing).	Bullish: FDA provides clear Category 1 classification for recommended peptides. Hims & Hers launches allowed peptides (sermorelin, glutathione, NAD+) by year-end 2026.	FDA announcements, company earnings calls, press releases, and investor presentations.	FDA.gov: Search for 'peptide compounding guidance'. Google Trends: 'sermorelin', 'glutathione', 'NAD+ therapy'. Reddit communities: r/peptides, r/longevity.	ClinicalTrials.gov: New peptide-related trials by Hims & Hers or partners.
Branded GLP-1 & Weight Loss Subscriber Growth	The strategic pivot to branded GLP-1s and sustained weight loss subscriber growth are critical for overall revenue acceleration and establishing market leadership in a high-demand category.	Net new subscriber additions (Q2: 300,000, total nearly 3 million). Hers brand annual revenue run rate (target: >$1 billion for 2026). Retention and cancellation rates for weight loss cohorts, especially those with new AI experience.	Bullish: Sustained high net subscriber additions (e.g., >300,000 per quarter), Hers brand exceeding $1 billion annual revenue, and improving retention/lower cancellations for weight loss cohorts.	Company earnings calls, investor presentations, and press releases.	Google Trends: 'Wegovy Hims', 'Zepbound Hers', 'weight loss telemedicine'. Reddit communities: r/Hims, r/Hers, r/semaglutide.	Consumer transaction data (e.g., credit card data): Spending on Hims & Hers for weight loss. Similarweb: Web traffic to Hims & Hers weight loss pages.
Return to Positive Free Cash Flow	After a negative operating and free cash flow in Q2 2026, resuming positive free cash flow generation in the second half of the year is crucial for demonstrating financial discipline, funding growth, and reducing reliance on external financing.	Operating cash flow and free cash flow reported in Q3 and Q4 2026 earnings. Specific commentary on working capital management and the impact of the $400 million receivables facility.	Bullish: Positive operating and free cash flow reported in H2 2026, meeting the company's expectation to resume free cash flow generation.	Company earnings calls, SEC filings (10-Q, 10-K).	N/A	N/A
International Revenue Growth & Profitability	International expansion, bolstered by the Eucalyptus acquisition, is a key growth lever and diversifies revenue streams. Demonstrating strong growth and a clear path to profitability validates the global strategy.	International revenue contribution in Q3 and Q4 2026 (target: at least $600 million for full year 2026). Progress towards near breakeven adjusted EBITDA for the international segment. Growth in new international markets (Canada, Japan).	Bullish: International revenue meets or exceeds $600 million target for 2026 while maintaining near breakeven adjusted EBITDA.	Company earnings calls and investor presentations.	Google Trends: 'Hims UK', 'Hers Australia', 'Eucalyptus health Germany'. Local news/health publications in target international markets.	Apptopia/Sensor Tower: App downloads and usage in UK, Australia, Germany, Canada, Japan for Hims & Hers brands.

Key Reported Metrics, Reratings Triggers & Results3 rows

This segment is a key growth engine, demonstrating the success of global expansion efforts and the impact of the Eucalyptus acquisition. Continued strong growth

Upcoming print · 2026-11-02

Key reported metrics
Metric	Last period	Why it matters
International Revenue	$131 million (1700% y/y growth)	This segment is a key growth engine, demonstrating the success of global expansion efforts and the impact of the Eucalyptus acquisition. Continued strong growth and progress towards profitability are vital for revenue diversification and long-term value.
Adjusted EBITDA Margin	8% (+1.0pp)	This metric will show the immediate impact of strategic investments in AI and international expansion on profitability. Investors will watch for signs of operating leverage and progress towards the anticipated H2 improvement in EBITDA dollars.
Total Revenue	$753 million (40% y/y growth)	Total Revenue is the primary indicator of the platform's overall scale and growth. Q3 performance will be crucial for validating the acceleration post-strategic pivot in the weight loss business and international expansion, which is key for investor confidence.

Last reported · 2026-08-10

Key reported metrics			Rerating thresholds			Earnings results
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date	Actual reported	Hit target?	Notes
Adjusted EBITDA Margin	7%	This metric will show the immediate impact of strategic investments and the weight loss pivot on profitability. Investors will watch for signs of margin compression and progress towards the anticipated H2 improvement in EBITDA dollars.	An Adjusted EBITDA margin of 12% or higher for Q2 2026, significantly exceeding its implied 10% guidance for the quarter. Additionally, management must reaffirm or raise its full-year 2026 Adjusted EBITDA guidance, ideally towards the higher end of the current $275 million to $350 million range.	Hitting this threshold demonstrates HIMS' business model sustainability amidst GLP-1 pricing pressure and regulatory uncertainty. It validates verticalization as a structural cost advantage, enabling margin expansion, de-risking the 'value trap' narrative, and confirming the path to its ambitious 2030 EBITDA target.	2026-08-10	8% (+1.0pp)	No	The company reported an Adjusted EBITDA margin of 8% for Q2 2026, which was below the 12% rerating trigger. While management raised the full-year revenue outlook, the full-year Adjusted EBITDA guidance range was updated to $275 million to $325 million, with a midpoint margin of 9%, which is not towards the higher end of the previous range ($275 million to $350 million). Management noted that gross margins were 64%, down approximately 6 points quarter-over-quarter, reflecting strategic investments in weight loss and international expansion, which are expected to keep gross margins below historical levels. GAAP net income was a loss of $86 million, impacted by $81 million of non-recurring acquisition, restructuring, and legal costs.
International Revenue	900%	This segment is a key growth engine, demonstrating the success of global expansion efforts and the impact of acquisitions like ZAVA and Livewell, with the planned Eucalyptus acquisition expected to close in 2H 2026.	International Revenue for Q2 2026 needs to maintain or exceed 900% year-over-year growth, reaching at least the analyst estimate of approximately $115 million. Additionally, the company must demonstrate clear progress toward international segment profitability, with the international business expected to break even within 12-18 months after the Eucalyptus acquisition, which closed in June 2026, is fully integrated.	Hitting this threshold validates HIMS's global expansion strategy and acquisition effectiveness, diversifying revenue and expanding the addressable market. It mitigates margin compression concerns, reinforcing the thesis of HIMS as a growing, consumer-centric health ecosystem, justifying a higher valuation.	2026-08-10	$131 million (1700% y/y growth)	Yes	International revenue significantly exceeded the rerating trigger, increasing over 17-fold (1700%) year-over-year to $131 million, surpassing the $115 million analyst estimate. The Eucalyptus acquisition, which closed in June 2026, contributed approximately $40 million to Q2 revenue. Management expects the international business to generate at least $600 million in revenue for the full year 2026 and operate at or near breakeven on an Adjusted EBITDA basis, demonstrating clear progress towards profitability. This strong performance validates the global expansion strategy.
Total Revenue	4%	Total Revenue is the primary indicator of the platform's overall scale and growth. Management raised the full-year guidance, making Q2 performance crucial for validating the acceleration post-strategic pivot in the weight loss business.	For Hims & Hers Health, Inc. (HIMS) to rerate higher, the company needs to report Q2 2026 Total Revenue significantly exceeding its guidance of $680 million to $700 million, ideally surpassing analyst consensus estimates of approximately $690 million to $700 million and approaching or exceeding $750 million. Additionally, HIMS must raise its full-year 2026 revenue guidance above the current range of $2.8 billion to $3.0 billion.	Exceeding these revenue targets is crucial as it would validate HIMS's strategic pivot to branded GLP-1s and new specialties, demonstrating sustainable volume growth and revenue diversification. This performance would restore investor confidence in its durable, high-growth proactive health platform, justifying a higher valuation, especially given recent concerns about slowing growth and a high valuation.	2026-08-10	$753 million (40% y/y growth)	Yes	Total revenue for Q2 2026 was $753 million, representing nearly 40% year-over-year growth, significantly exceeding both the company's guidance ($680 million to $700 million) and analyst consensus estimates ($690 million to $700 million). Furthermore, management raised its full-year 2026 revenue outlook to $3.1 billion to $3.3 billion, up from the previous range of $2.8 billion to $3.0 billion. This strong performance and raised guidance validate the strategic pivot to branded GLP-1s and new specialties, demonstrating sustainable volume growth.

Key Questions

Can Hims & Hers sustain the acceleration in domestic and international revenue growth, particularly in the competitive weight loss market and new international

Can Hims & Hers sustain the acceleration in domestic and international revenue growth, particularly in the competitive weight loss market and new international markets, to meet its raised full-year 2026 revenue outlook of $3.1 billion to $3.3 billion?

Question 2: Can Hims & Hers achieve the anticipated 'meaningful step-up' in adjusted EBITDA dollars in the second half of 2026, demonstrating operating leverage and the expected payback from AI investments, despite continued gross margin compression from scaling branded GLP-1s and international operations?
Question 3: Will the FDA provide the 'full and final rule making' necessary for Hims & Hers to launch the 6-7 recommended peptides, and can the company successfully scale its newly acquired international operations (Eucalyptus) towards profitability while expanding into new specialties like testosterone and already allowed peptides by year-end?

Earnings Transcript Summary4 rows

2026-08-10 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Investment in AI and technology to deliver a unique, integrated, and personalized health experience, driving efficiency and deeper customer relationships. 2. Expanding infrastructure to support more complex categories (e.g., testosterone, peptides) and a wider spectrum of customer needs, enabling faster and larger-scale entry into new markets. 3. Global expansion and leveraging scale to become a leading consumer health platform worldwide, including strategic acquisitions (Eucalyptus) and partnerships (Novo Nordisk).	Call Takeaway & ToneThe call conveyed a strong sense of accelerating growth, particularly in the domestic business and through significant international expansion via the Eucalyptus acquisition. Management emphasized strategic investments in AI and technology to enhance the customer experience and drive efficiency, as well as expanding into complex categories like weight loss and testosterone. Despite acknowledging near-term margin compression due to these investments, the overall tone was highly confident, ambitious, and strategic, underscoring the company's belief in its long-term vision and ability to achieve its 2030 financial targets.	Prior Quarter'S Y/Y Growth By SegmentTotal Revenue (Q1 2026): 4% year-over-year growth. Domestic Revenue (Q1 2026): -8% year-over-year decline. International Revenue (Q1 2026): Nearly tenfold (900%) year-over-year growth.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Peptides Opportunity and Timeline: Analysts questioned the go-to-market timeline once FDA guidance is provided, compliance readiness, and whether they still intend to let others go first. Management responded that they have made "incredible progress" on clinical guidelines and supply chain, are confident to move "extremely quickly" if the FDA moves peptides to Category 1, and are already moving forward with allowed peptides like sermorelin, glutathione, and NAD+ by year-end. For the 6-7 peptides, they are waiting on "full and final rule making from the FDA". 2. AI Investments and Longer-Term Vision (Real-time health score): Analysts asked about bringing together all data (labs, wearables, treatment, outcome) for a real-time health score, early flagging of problems, and if this is actively being built. Management confirmed this is their vision, aiming to create an ecosystem of healthcare professionals and tools powered by AI to provide 24/7 proactive and preventative care, making "concierge care" universally accessible and affordable, potentially through membership or freemium offerings. 3. Novo Nordisk Partnership (Retention/Engagement & Deepening Relationship): Analysts inquired about the retention and engagement of branded cohorts compared to historical products and how Hims & Hers plans to deepen the Novo Nordisk relationship. Management expressed excitement about the collaborative relationship, highlighting Hims & Hers' role in expanding access to Wegovy and the potential for increased collaboration on strategic markets and data sharing. They noted that retention is "within expectations" and improving with the new immersive AI-powered experience, leading to lower cancellation rates.	Revenue SegmentsTotal Revenue: 40% year-over-year growth. Domestic Revenue: 16% year-over-year growth. International Revenue: Over 17-fold year-over-year growth.

2026-05-11 · 2026Q1 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Accelerating growth and market leadership: Management is focused on expanding the U.S. business with new specialties like weight loss (pivoting to branded GLP-1s), testosterone, menopause, and labs, alongside aggressive international expansion, notably through the planned acquisition of Eucalyptus. 2. Leveraging data and AI for enhanced customer experience and care quality: The company is building a smarter, more agile platform by integrating AI agents, such as the Labs AI health care agent, an AI copilot for providers, and an upcoming AI weight loss companion, to personalize care, improve outcomes, and deepen customer relationships. 3. Strategic investments in verticalized infrastructure and technology: Hims & Hers is investing in facilities to expand capabilities and operating efficiency, including at-home blood collection technology (YourBio) and a U.S.-based peptide facility, to support new offerings, reduce costs, and ensure high safety and quality standards.	Call Takeaway & ToneThe call conveyed that Hims & Hers is undergoing a significant strategic transition, particularly in its weight loss business by pivoting to branded GLP-1s, and is aggressively investing in new specialties (labs, testosterone, menopause, peptides) and international expansion. Management acknowledged that these investments and strategic shifts would create near-term GAAP financial volatility and margin pressure. However, the overall tone was confident and ambitious, emphasizing accelerating growth, leveraging AI and verticalized infrastructure, and a strong conviction in achieving its ambitious 2030 targets.	Prior Quarter'S Y/Y Growth By SegmentTotal Revenue: 28% year-over-year. International Revenue: 825% year-over-year. U.S. Operations Revenue: Not explicitly stated as a percentage for Q4 2025.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Weight Loss Strategic Pivot (Branded vs. Compounded GLP-1s) and its Financial Impact: Analysts questioned the economics of branded versus compounded products, the subscriber transition, and the pivot's effect on guidance. Management responded that branded and compounded products are roughly comparable on a dollar basis, the pivot significantly expands the addressable market, and early success signals (over 100,000 new weight loss subscribers per month) reinforced the decision to elevate the guide. 2. Peptides Opportunity and Readiness: Analysts inquired about the company's long-term peptide strategy, potential differentiation, competitive advantages from its domestic supply chain, and readiness for market entry. Management emphasized a strategy of being 'best in market' rather than 'first to market,' focusing on physician oversight, a safe and verticalized U.S. supply chain, and rigorous clinical protocols, noting the instinctively large demand driven by proactive health trends. 3. Gross Margin Compression and H2 EBITDA Ramp: Analysts pressed on the expected degradation in gross margins and the confidence in achieving higher incremental EBITDA margins in the second half of the year. Management explained that gross margins are expected to compress by a couple of points in coming quarters due to the strategic pivot and scaling lower-margin specialties (weight loss, labs, international). They expressed high conviction in the H2 EBITDA ramp, attributing it to the compounding effect of monthly cohorts from shorter shipping cadences, operating leverage in G&A, and continued marketing efficiency gains.	Revenue SegmentsTotal Revenue: 4% year-over-year to $608 million. International Revenue: Nearly tenfold (900%) year-over-year to $78 million. U.S. Operations Revenue: Temporarily pressured (no specific percentage given).

2026-02-23 · 2025Q4 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1) Diagnostics and devices innovation to expand the health platform (Labs, YourBio, wearables integration). 2) AI as a critical layer to personalize care and scale operations (data, AI tools, proactive messaging). 3) Deeper data and more proactive, personalized treatments, plus international expansion and category diversification to reach 2030 targets.	Call Takeaway & ToneThe call framed Hims & Hers as aggressively evolving into a global, consumer-centric proactive health platform. Near-term margin pressures and some revenue timing headwinds exist from shipping cadence changes and category transitions, but management conveyed confidence in leveraging a strong balance sheet and strategic investments to drive long-term growth and a path to 2030 targets. Tone: confident and ambitious.	Prior Quarter'S Y/Y Growth By SegmentHims US: >40% YoY in Q3 2025; Hers US: triple-digit YoY in Q3 2025; International: not disclosed in Q3 2025 transcript.	3 Things Analysts Most Pressed On (And Mgmt Responses)1) GLP-1 regulatory risk and potential branded Wegovy partnership with Novo Nordisk; mgmt response: pursuing branded Wegovy alongside compounded options and leveraging verticalization to lower prices while aiming to preserve long-term margins. 2) Margin expansion pause due to investments in technology and infrastructure; mgmt response: these investments are high-ROI and expected to drive future growth and free cash flow. 3) Durability of growth and mix shift away from GLP-1 toward Labs, menopause, low testosterone and other offerings; mgmt response: diversification strategy supported by labs/menopause/low-T and international expansion to sustain growth and LTV.	Revenue SegmentsU.S. Hims revenue growth: over 30% YoY in 2025; U.S. Hers revenue growth: triple-digit YoY in 2025; International revenue growth: almost 400% YoY in 2025 to $134 million.

2025-11-03 · 2025Q3 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Verticalization and Infrastructure: Expanding facility footprint to over 1 million square feet to support internal 503A sterile compounding, which management believes establishes a 'gold standard' for safety and allows for price reductions in GLP-1 and testosterone treatments. 2. Proactive Health and Diagnostics: Launching whole-body lab testing by year-end 2025 and a Longevity specialty in 2026 to shift the platform from reactive treatment of conditions to proactive health management. 3. Global Scale: Integrating the Zava acquisition to reach 200 million adults in Europe and preparing for a Canada launch in 2026, targeting a $1 billion+ international revenue opportunity.	Call Takeaway & ToneThe takeaway is that Hims & Hers is aggressively evolving from a telehealth provider for specific conditions into a vertically integrated, global 'proactive health' platform. While the company is facing near-term margin pressure and revenue headwinds from shipping cadence changes and segment transitions, management is 'leaning in' to its $1.1 billion cash position to fund massive expansion in diagnostics and longevity. The tone was extremely confident and ambitious, characterized by a 'build the future' mentality.	Prior Quarter'S Y/Y Growth By SegmentIn Q2 2025, Total Revenue grew 52% y/y (indicating a slight deceleration to 49% in Q3). Subscriber growth in Q2 2025 was 43% y/y (decelerating to 20% y/y in Q3, though management highlighted specific segment strengths).	3 Things Analysts Most Pressed On (And Mgmt Responses)1. GLP-1 Strategy and Novo Nordisk Partnership: Analysts questioned the impact of price cuts and the status of discussions with Novo Nordisk. Management responded that they are in active discussions to offer branded Wegovy alongside compounded options and that verticalization allows them to lower prices while maintaining long-term margin targets. 2. Margin Compression and Investment: Analysts pressed on the 'temporary pause' in margin expansion due to increased spending. Management explained that heavy investments in tech talent, AI-assisted tools, and infrastructure are high-ROI initiatives that will drive the next phase of growth and long-term free cash flow. 3. Core Business Growth Deceleration: Analysts asked about slowing growth in legacy segments like sexual health. Management responded that they are intentionally transitioning users from generic on-demand solutions to personalized daily treatments, which creates a short-term headwind but will lead to more durable recurring growth and acceleration in H2 2026.	Revenue SegmentsTotal Revenue: 49% y/y growth; Hers Brand: Near or above triple-digit y/y growth; Hims Brand (Subscribers): >40% y/y growth when excluding the sexual health transition impact; Weight Loss Specialty: On track for >$725M in 2025 revenue.

Transcript Tidbits4 rows

2026-08-10

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketHims & Hers welcomed over 300,000 subscribers in Q2 2026, bringing its global subscriber base to nearly 3 million people, rivaling some of the largest healthcare systems in the U.S.. The company's global reach, combined with technology and infrastructure, is expanding access to high-quality care. The Hers weight loss experience is driving meaningful change for customers. Testosterone is scaling faster than any other specialty outside of weight loss, with plans to expand into injectable and oral TRT before year-end, and extend this model to other specialties. The company is developing a best-in-class peptides experience, including U.S.-manufactured products, clinical guidance, and ongoing blood testing, with plans to offer already allowed peptides like sermorelin, glutathione, and NAD+ before the end of the year. The acquisition of Eucalyptus in June 2026 made Hims & Hers the leading global consumer health platform, with three international markets outside the U.S. now pacing above a $100 million annual run rate. This global expansion aims to deliver a truly personal, accessible, and effective weight management experience worldwide and across all specialties. Collaborations with pharmaceutical innovators like Novo Nordisk are expanding the addressable market, making Hims & Hers the largest digital platform for world-class weight loss experiences globally. Domestic revenue growth accelerated to 16% year-over-year in Q2, driven by the pivot to expand branded weight loss offerings. Hers is on track for over $1 billion in revenue this year, and low testosterone is expected to become the sixth U.S. specialty to reach a $100 million annual revenue run rate in coming quarters. The U.K., Australia, and Germany are each generating over $100 million in annualized revenue, with Canada also on track to join this group. Eucalyptus contributed approximately $40 million in Q2 revenue, further accelerating the existing international business, which grew 13% quarter-over-quarter organically. The company sees low-hanging fruit in bringing core U.S. specialties like testosterone replacement therapy, menopause therapy, dermatology categories (men's and women's hair, sexual health), and peptides to its international markets.	About CompetitionHims & Hers believes its investment in AI and technology delivers a health experience no other company can replicate, building something entirely new and increasingly difficult to replicate. Its AI-native platform aims to deliver a unified health experience that no other peer or LLM can match, supporting customers through their entire health journey unlike frontier AI companies. The company differentiates itself by making its platform completely AI-native, creating an integrated, personal experience, rather than just tacking on minor improvements to existing systems. Hims & Hers sees its advantage as being an everyday partner to customers, not just a chatbot, believing this is something only they can do well. The company asserts its growing scale and increasing investment in technology and infrastructure make it structurally more efficient than anyone else in healthcare, allowing it to play offense with a balance sheet and cost structure others cannot sustain. They believe their capabilities and scale provide structural advantages for investing in key growth areas like weight loss and international markets in ways competitors cannot. Delivering more for less is how they extend their platform's advantages, a feat few in consumer health can match. The company's global scale is becoming a competitive advantage, expanding its total addressable market and value to industry partners, strengthening network effects. Its closed-loop proprietary data flywheel, encompassing consumer intake, diagnosis, treatment, provider decisions, and outcomes in a single stack, is difficult for competitors to recreate. The verticalized infrastructure and U.S.-based peptide manufacturing facility provide advantages in quality, purity, reliability, and brand trust that will be difficult for others to match.	About The Broader IndustryThe healthcare industry is finally adopting a consumer-centric model, similar to entertainment, travel, and transportation, with Hims & Hers leading a transformation that removes middle layers to ensure direct access from innovators to consumers. While AI models are becoming a commodity, on their own, they are an incomplete part of a wider health experience. The weight loss market is rapidly evolving with more form factors and lower prices. Pharma, biotech, and diagnostic companies are increasingly relying on platforms like Hims & Hers to reach more people with innovative treatments and services. There is a growing trend of customers seeking proactive and continuous care, informed by health insights, to not just get healthy but stay healthy. In the emerging peptide category, the standard bearers will be companies prioritizing physician-first, transparent experiences focused on successful customer outcomes, contrasting with the current unregulated, inconsistent gray market. There is a growing emergence, likely provoked by the GLP-1 category, of patients seeking to be more proactive with health, focusing on preventative and longevity-focused care rather than just acute issues.	Where Things Are HeadedHims & Hers expects its AI investment to pay for itself in short order and plans to roll out its AI-native experience to more customers globally, potentially becoming the backbone for health platforms beyond Hims & Hers. Modular core components will allow the company to stand up new categories and markets faster and at lower costs, translating to lower prices for customers. The company plans to add new AI talent, develop existing talent, and open an AI R&D lab in Menlo Park. They anticipate improved quality and depth of care, leading to longer customer retention and new customer acquisition, with a transformative impact on the business. The vision is to offer preventative screening, innovative medications, and a care team for an affordable monthly price, tailored for individual lives. The company expects to resume free cash flow generation in the second half of the year, with AI investments paying back within 12 to 18 months. They anticipate unlocking more value for weight loss subscribers by year-end through lower prices and/or additional tools. Efficiencies will be redeployed to accelerate international business growth, with these markets expected to emerge as meaningful profit centers as they scale. Investments will continue in operational capabilities and clinical oversight for new, higher-complexity offerings like injectable testosterone and, if regulatory landscape allows, peptide therapies. For Q3 2026, revenue is anticipated to be $880 million to $900 million (47% to 50% YoY increase), with adjusted EBITDA between $75 million and $95 million (10% margin at midpoint). Full-year 2026 revenue outlook is raised to $3.1 billion to $3.3 billion (32% to 41% YoY increase), with adjusted EBITDA expected between $275 million and $325 million (9% margin at midpoint). Gross margin dynamics are expected to persist through H2 due to branded weight loss and international revenue growth. A meaningful step-up in adjusted EBITDA dollars is expected in H2 due to compounding weight loss cohorts and operating expense leverage. The international business is expected to generate at least $600 million in revenue in 2026, operating at or near breakeven as scale is prioritized. The company reaffirms its 2030 ambitions of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. A natural membership offering and a powerful freemium offering are envisioned for the coming year or two, aiming to make concierge-level proactive, preventative, always-on care universally accessible and affordable. For peptides, the company is awaiting full and final rule-making from the FDA before bringing the recommended peptides to market, but will move forward with other wellness and peptide offerings like sermorelin, glutathione, and NAD+ by year-end. The company expects a significant acceleration in both U.S. revenue and EBITDA in the back half of the year. Hims & Hers expects to return to net income profitability in 2027.	Updates On ThemePeptide	Broader Themes EmergingProactive Longevity & Diagnostics: There is a growing trend of patients seeking to be more proactive with their health, focusing on preventative and longevity-focused care, rather than solely addressing acute issues. This is evident in the demand for emerging therapies like peptides and the growth of categories such as lab testing, testosterone, and menopause, where individuals are taking more control of their health.	Bullish-Leaning Quotes (Short)This quarter, we made significant progress on building a first-of-its-kind health experience that proves it is possible to deliver access to world-class care on a global scale at a reasonable price. Nearly 3 million customers believe in a future of health that is proactive, personal and built for their lives, and we are thrilled to be the partner bringing it to them every day. In the second quarter, we welcomed more than 300,000 subscribers, bringing our global subscriber base to nearly 3 million people. Our AI-centric technical strategy is the difference between adding a feature and reimagining the entire customer experience. Hers customers using the new care experience are sending 3x as many messages on the platform with AI answering 80% of their questions to support their treatment journey. In just a few months, the internal updates we've rolled out are powerful enough that we have meaningfully reduced how much we rely on agentic AI customer support vendors. testosterone is scaling faster than any other specialty outside of weight loss. In June, we became the leading global consumer health platform when we closed our acquisition of Eucalyptus. We are now giving more people access to a world-class weight loss experience than any other digital platform in the world. revenue grew nearly 40% year-over-year to more than $753 million. Adjusted EBITDA in the quarter was $60 million, representing an 8% adjusted EBITDA margin. For the full year, we are raising our 2026 revenue outlook to $3.1 billion to $3.3 billion. All of which reinforce our confidence in achieving our 2030 ambitions of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. The short answer to that question is yes. We are also hiring.	Bearish-Leaning Quotes (Short)operating cash flow momentum took a pause due to the increased working capital demands associated with our rapidly expanding branded weight loss offering. During the quarter, operating cash flow was negative $36 million and free cash flow was negative $68 million. GAAP net income was a loss of $86 million, which was impacted by the previously mentioned nonrecurring acquisition, restructuring and legal costs. Gross margins in the second quarter were 64%, down approximately 6 points quarter-over-quarter on an adjusted basis. As branded weight loss products and international revenue become a larger portion of the business, we expect gross margins will remain below the levels we have historically achieved. Our guidance is designed to preserve the flexibility to lean further into the investment priorities outlined today as opportunities materialize.	HiringIn the coming months, Hims & Hers plans to add new AI talent to the team, continue to develop existing talent, and open an AI R&D lab in Menlo Park. The company is actively hiring, as indicated by the statement, "The short answer to that question is yes. We are also hiring. So you're able to piece a lot of that together, so please apply." AI is intended to elevate clinicians by taking routine work off their plates, allowing them to focus on judgment and complex decisions, rather than replacing them.

2026-05-11

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketThe U.S. business is positioned to accelerate with the introduction of new specialties like testosterone, menopause, and labs. The expanding selection of branded GLP-1 solutions is driving accelerating momentum in the weight loss business, with over 100 million adults in the U.S. struggling with weight. Within weeks of introducing direct access to Novo Nordisk GLP-1 products, the platform fulfilled over 125,000 shipments for Wegovy. Providers can now also send prescriptions for Zepbound to LillyDirect pharmacy. The planned acquisition of Eucalyptus in the second half of this year will extend leadership across Australia, the U.K., Germany, Japan, and Canada, with the opportunity to impact hundreds of millions of people. The introduction of branded weight loss products is expanding the addressable market significantly, with the company on track to add over 100,000 new subscribers per month in the weight loss specialty. New categories like labs, menopause, and testosterone are iterating domestically before expanding to other geographic regions within 6 to 9 months.	About CompetitionGlobal scale is quickly becoming a competitive advantage, expanding TAM and value to industry partners, strengthening network effects. The company is deepening customer relationships by filling gaps in traditional care with proactive offerings. Continued investment in data and technology infrastructure is building an agile platform that gets smarter with every new customer, creating a powerful, hard-to-replicate data set. The platform is becoming a go-to for pharma, biotech, and diagnostic companies to reach more people. Hims & Hers is rapidly becoming the world's largest consumer health platform and sees itself as the best global platform for industry partners due to global presence and personalized experience. The closed-loop proprietary data flywheel is difficult for competitors to recreate, as it's one of the only platforms where consumer intake, diagnosis, treatment, provider decisions, and outcomes live in a single stack. The integration of providers, portables, and regulatory infrastructure creates a unified care model that sets it apart from traditional LLMs or frontier AI labs. The verticalized infrastructure and domestic supply chain, including a U.S.-based peptide facility, provide advantages in quality, purity, reliability, and brand trust that will be difficult for others to match.	About The Broader IndustryThe weight loss market is evolving rapidly with more form factors and lower prices. Platforms like Hims & Hers are increasingly relied upon by pharma, biotech, and diagnostic companies to reach more people with innovative treatments and services. More customers are seeking proactive and continuous care, informed by health insights, to not just get healthy but stay healthy. In the emerging peptide category, the standard bearers will be companies prioritizing physician-first, transparent experiences focused on successful customer outcomes, contrasting with the current unregulated, inconsistent gray market. There is a growing emergence, likely provoked by the GLP-1 category, of patients seeking to be more proactive with health, focusing on preventative and longevity-focused care rather than just acute issues.	Where Things Are Headed2026 is a year of accelerating growth, reinforcing confidence in ambitious 2030 targets. Hims & Hers aims to become an everyday health partner for millions more globally. The planned acquisition of Eucalyptus is expected to close in the second half of this year. The company will continue investing in technology in the near term, expecting benefits to cascade across the platform. Investments in talent will support expansion into complex offerings like injectable low testosterone treatments and new offerings like peptides as the regulatory landscape evolves. The company expects to return to net income profitability in 2027. For the full year 2026, revenue outlook is raised to $2.8 billion to $3 billion, with adjusted EBITDA expected between $275 million and $350 million. Gross margins are expected to compress as the company prioritizes scaling weight loss, labs, and international markets. A meaningful step-up in adjusted EBITDA dollars is anticipated in the third and fourth quarters. Technology investments are expected to yield efficiency benefits starting in 2027. The company is confident in replicating its success and establishing category leadership in international markets like Canada, the U.K., Australia, and other European countries, maintaining 2030 ambitions of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.	Updates On ThemePeptide	Broader Themes EmergingProactive Longevity & Diagnostics: There is a growing trend of patients seeking to be more proactive with their health, focusing on preventative and longevity-focused care, rather than solely addressing acute issues. This is evident in the demand for emerging therapies like peptides and the growth of categories such as lab testing, testosterone, and menopause, where individuals are taking more control of their health.	Bullish-Leaning Quotes (Short)2026 has proven to be a year of accelerating growth. Our U.S. business is positioned to accelerate as we introduce new specialties. Our global scale is quickly becoming a competitive advantage. Within weeks of this launch, we are on track to add north of 100,000 new subscribers per month within our weight loss specialty. We are rapidly becoming the world's largest consumer health platform. I have never been more confident that we are building the future of health. For the full year, we are raising our 2026 revenue outlook to $2.8 billion to $3 billion.	Bearish-Leaning Quotes (Short)In the first quarter, revenue grew 4% year-over-year to $608 million. Adjusted EBITDA was $44 million, representing a 7% adjusted EBITDA margin. We incurred approximately $33 million of restructuring costs, primarily consisting of the write-downs related to our compounded GLP-1 supply chain that now face risk of obsolescence. Approximately $28 million of onetime charges negatively impacted gross margins by roughly 5 points in the first quarter. GAAP net income declined to a loss of $92 million in Q1. We expect gross margins to compress as we prioritize scaling areas such as weight loss, labs and international markets. Near-term margin headwinds are expected in the second quarter as the majority of our weight loss specialty moves toward 1-month shipments.	HiringThe engineering team is lean and talented, driven by senior leaders. The AI organization has been built from scratch and now includes nearly 40 members, comprising senior AI engineers, applied scientists (PhDs from MIT, Berkeley), and seasoned leaders from top tech companies. The company expects to continue investing in talent and capabilities across technology and operations. Specifically, talent investments were made in Q1 to expand into more complex offerings like injectable low testosterone treatments and to prepare for new offerings such as peptides as the regulatory landscape evolves. AI is expected to reduce organizational and operational costs, enhancing service quality and meaningfully reducing the cost to serve consumers, with some efficiency benefits potentially emerging in 2027.

2026-02-23

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketExpanding TAM via new specialties (low testosterone, menopause, Labs) and rapid geographic expansion (Canada; U.K., Germany, France, Ireland, Spain; Australia and Japan via Eucalyptus; ZAVA and Livewell acquisitions) with 2.5M+ subscribers; 130+ biomarkers; aim for >$1B incremental international revenue in 3 years.	About CompetitionScalability and vertical integration as a moat; price reductions on GLP-1 to improve access and margins; active discussions with Novo Nordisk to offer branded Wegovy on the platform; potential regulatory scrutiny of GLP-1 compounding; competition from traditional providers as the platform expands into diagnostics and longevity.	About The Broader IndustryIndustry shifting from reactive treatment to proactive, preventative care; diagnostics and wearables integration; AI as a critical layer; mass-market at-home testing and data-driven personalization are becoming core to health platforms.	Where Things Are HeadedLong-term targets include $6.5B revenue and $1.3B adjusted EBITDA by 2030; international business expected to break even within 12–18 months after Eucalyptus closing; 2026 guidance for revenue and EBITDA; labs, testosterone, menopause and AI-enabled platform experiences to scale with ongoing international expansion.	Updates On ThemePremium	Broader Themes EmergingProactive Longevity & Diagnostics: broad shift to accessible, mass-market health diagnostics and proactive care across life stages.	Bullish-Leaning Quotes (Short)"The opportunity is significant."; "Hers brand is on pace to deliver revenue of over $1 billion in 2026."; "Active discussions with Novo Nordisk to make Wegovy injections available through our platform."; "In just 90 days, we created 3 distinct new entry points to our platform."	Bearish-Leaning Quotes (Short)"Gross margins declined approximately 2 points quarter-over-quarter to 72%."; "Headwinds in the fourth quarter from shorter shipment cadences."; "Approximately $65 million revenue headwind in Q1 2026 from shipping cadences in weight loss."	HiringInvestments in technology and AI talent, safety/compliance staffing, and leadership hires; international headcount growth and expansion of facilities to over 1 million square feet; notable marketing spend such as the 60-second Super Bowl ad as part of brand education.

2025-11-03

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)
About Expanding Eligible MarketHims & Hers is aggressively expanding its TAM through new specialties including low testosterone, perimenopause, and menopause. The company is launching comprehensive whole-body lab testing before year-end 2025 and a longevity specialty in 2026. Geographically, they are expanding into Canada (targeting 2/3 of adults who are overweight) and leveraging the Zava acquisition to reach 200 million adults across the U.K., Germany, France, Ireland, and Spain. They are also in active discussions with Novo Nordisk to offer Wegovy and oral semaglutide.	About CompetitionThe company views its scale as a primary competitive advantage, allowing it to act as a 'powerful curator' of health solutions. They are positioning themselves against traditional providers by offering personalized, high-touch care that is often stigmatized or hard to access. To maintain a leadership position in weight loss, they strategically reduced compounded GLP-1 prices by up to 20%. They are also preparing for the 2026 entry of generic semaglutide by engaging with leading generic manufacturers.	About The Broader IndustryThe industry is shifting from reactive treatment of existing conditions to proactive, preventative health management. There is a significant gap in specialized care, noted by the fact that only 30% of OB/GYN residency programs offer formal training on menopause. The company also highlights a 'green list' of FDA-registered GLP-1 API suppliers, signaling a tightening of regulatory and quality standards in the compounding space.	Where Things Are HeadedHIMS is tracking toward its 2030 goal of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. The Hers brand is expected to reach $1 billion in annual revenue by 2026. The company is transitioning its sexual health business from on-demand generics to daily personalized treatments, a shift expected to normalize by late 2026. Future growth will be driven by 'verticalizing' sterile compounding infrastructure and integrating AI-assisted tools like nutritional coaches.	Updates On ThemePremium	Broader Themes EmergingProactive Longevity & Diagnostics: A shift toward 'the great equalization' of high-end diagnostics, moving from $5,000+ boutique testing to affordable, mass-market whole-body screening for early detection of cancer and cardiovascular disease.	Bullish-Leaning Quotes (Short)"Subscribers using personalized solutions grew 50% year-over-year."; "Hers brand... on pace to deliver revenue of over $1 billion in 2026."; "Active discussions with Novo Nordisk to make Wegovy injections... available through our platform."; "Marketing as a percentage of revenue was 39%, representing more than 6 points of leverage."	Bearish-Leaning Quotes (Short)"Gross margins declined over 2 points quarter-over-quarter to 74%."; "Headwinds in the fourth quarter from shorter shipment cadences."; "Temporary pause in year-over-year margin expansion."; "Continued moderation in our on-demand sexual health business."

Notes2 rows

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-02-23	Hims & Hers reported Q4 revenue of $618M (up 28% YoY) and full-year revenue of $2.35B, guiding 2026 revenue of $2.7-2.9B with adjusted EBITDA of $300-375M. Growth drivers include Labs, menopause, low-T and faster international expansion. The market reacted modestly negative: stock -0.32% on earnings day, underperforming SPY, suggesting skepticism about GLP-1 exposure and near-term margins despite a clear long-term platform pivot to proactive care and 2030 targets.	Other	Neutral	https://investors.hims.com/news-releases/news-release-details/hims-hers-health-reports-fourth-quarter-and-full-year-2025-earnings	-0.32% (vs SPY: -1.05%)
2026-08-10	Hims & Hers reported strong Q2 revenue growth and raised its 2026 outlook, driven by international expansion and AI investments. However, gross margins compressed, and Q2 saw negative free cash flow due to strategic investments and FTC litigation. The market reacted negatively, with the stock underperforming SPY, indicating concerns over profitability and legal challenges despite the positive growth narrative.	Earnings Transcript	Negative		-5.67% (vs SPY: -5.57%)

Upcoming Events2 rows

Catalyst ID	Estimated Timing	Estimated Date Start	Estimated Date End	Catalyst	Why It Matters	Ticker Or Theme Specific	Transcript Date	Source Type
HIMS_8ce0db05	within 12 to 18 months	2027-02-23	2027-08-23	Management target for the collective international business (inclusive of Eucalyptus) to reach break-even on an adjusted EBITDA basis within 12–18 months.	Achievement would validate international scaling playbook, reduce consolidated margin drag and accelerate path to 2030 EBITDA targets; failure to reach break-even would prolong international margin pressure and may require additional investment or slower expansion.	Ticker	2026-02-23	earnings_transcript
HIMS_7a775872	in 2026	2026-01-01	2026-12-31	Integration and scaling of YourBio's microneedle at‑home blood-sampling technology into Hims & Hers' Labs offering (post-close integration to enable at‑home diagnostics).	Successful integration could accelerate Labs adoption, increase addressable market and data-driven personalization (raising LTV and cross-sell), while delays or poor execution would slow diagnostic-led growth and reduce anticipated unit-economics improvements.	Ticker	2026-02-23	earnings_transcript